| Autor: |
de Jong FJM; Royal Netherlands Navy Diving and Submarine Medical Centre, 1780 CA Den Helder, The Netherlands.; Department of Anesthesiology, Amsterdam UMC, Location AMC, 1100 DD Amsterdam, The Netherlands., Wingelaar TT; Royal Netherlands Navy Diving and Submarine Medical Centre, 1780 CA Den Helder, The Netherlands.; Department of Anesthesiology, Amsterdam UMC, Location AMC, 1100 DD Amsterdam, The Netherlands., Brinkman P; Department of Pulmonology, Amsterdam UMC, Location AMC, 1100 DD Amsterdam, The Netherlands., van Ooij PAM; Royal Netherlands Navy Diving and Submarine Medical Centre, 1780 CA Den Helder, The Netherlands.; Department of Pulmonology, Amsterdam UMC, Location AMC, 1100 DD Amsterdam, The Netherlands., Maitland-van der Zee AH; Department of Pulmonology, Amsterdam UMC, Location AMC, 1100 DD Amsterdam, The Netherlands., Hollmann MW; Department of Anesthesiology, Amsterdam UMC, Location AMC, 1100 DD Amsterdam, The Netherlands., van Hulst RA; Department of Anesthesiology, Amsterdam UMC, Location AMC, 1100 DD Amsterdam, The Netherlands. |
| Abstrakt: |
The COMEX-30 hyperbaric treatment table is used to manage decompression sickness in divers but may result in pulmonary oxygen toxicity (POT). Volatile organic compounds (VOCs) in exhaled breath are early markers of hyperoxic stress that may be linked to POT. The present study assessed whether VOCs following COMEX-30 treatment are early markers of hyperoxic stress and/or POT in ten healthy, nonsmoking volunteers. Because more oxygen is inhaled during COMEX-30 treatment than with other treatment tables, this study hypothesized that VOCs exhaled following COMEX-30 treatment are indicators of POT. Breath samples were collected before and 0.5, 2, and 4 h after COMEX-30 treatment. All subjects were followed-up for signs of POT or other symptoms. Nine compounds were identified, with four (nonanal, decanal, ethyl acetate, and tridecane) increasing 33-500% in intensity from before to after COMEX-30 treatment. Seven subjects reported pulmonary symptoms, five reported out-of-proportion tiredness and transient ear fullness, and four had signs of mild dehydration. All VOCs identified following COMEX-30 treatment have been associated with inflammatory responses or pulmonary diseases, such as asthma or lung cancer. Because most subjects reported transient pulmonary symptoms reflecting early-stage POT, the identified VOCs are likely markers of POT, not just hyperbaric hyperoxic exposure. |
